<sub id="dccn5"></sub><strike id="dccn5"><sup id="dccn5"><mark id="dccn5"></mark></sup></strike>
  1. <wbr id="dccn5"><legend id="dccn5"></legend></wbr>

    <nav id="dccn5"></nav>

  2. A POWERFUL RESEARCH AND
    DEVELOPMENT ENGINE

    Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

    Interact with the Regeneron Pipeline

    Select Therapeutic Area(s):
    Select Phase(s):
    Select Collaborator(s):

    Displaying item(s)

    Clear Filters

    Phase 1 trials Phase 1 trials
    • CEMIPLIMAB*
      PD-1 Antibody Cancer
    • REGN3767
      LAG-3 Antibody Cancer
    • REGN1979
      CD20xCD3 Antibody Cancer
    • REGN4018*
      MUC16xCD3 Antibody Cancer
    • REGN5093
      METxMET Antibody Cancer
    • REGN5458*
      BCMAxCD3 Antibody Cancer
    • REGN5459*
      BCMAxCD3 Antibody Cancer
    • REGN5678
      PSMAxCD28 Antibody Cancer
    • REGN5713-5714-5715
      Betv1 Antibody Birch Allergy
    Phase 2 trials Phase 2 trials
    • AFLIBERCEPT
      VEGF Trap High-dose for wet age-related macular degeneration (AMD)
    • CEMIPLIMAB*
      PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
    • REGN1979
      CD20xCD3 Antibody Relapsed/refractory follicular lymphoma, non-Hodgkin lymphomas, diffuse large B-cell lymphoma
    • DUPILUMAB*
      IL-4R Antibody Grass allergy, peanut allergy
    • SARILUMAB*
      IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
    • REGN1908-1909
      Fel d 1 Antibody Cat allergy
    • REGN3500*
      IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis
    • REGN5069
      GFRα3 Antibody Osteoarthritis knee pain
    • REGN4461
      LEPR Antibody Generalized lipodystrophy
    • GARETOSMAB
      Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
    • EVINACUMAB
      ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
    • POZELIMAB
      C5 Antibody Paroxysmal nocturnal hemoglobinuria
    Phase 3 trials Phase 3 trials
    • AFLIBERCEPT
      VEGF Trap Retinopathy of Prematurity (ROP)
    • ALIROCUMAB*
      PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics
    • CEMIPLIMAB*
      PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)
    • REGN-EB3
      Ebola Virus Antibody Ebola virus infection
    • DUPILUMAB*
      IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatrics, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, bullous pemphigoid, chronic spontaneous urticaria
    • SARILUMAB*
      IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis
    • EVINACUMAB
      ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
    • FASINUMAB?
      NGF Antibody Chronic pain from osteoarthritis of the knee or hip

    No results found, please adjust your filter selection and try again.

    * In collaboration with Sanofi

    ? In collaboration with Teva and Mitsubishi Tanabe

    This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

    草莓视频